Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation

Oslo, Norway, 5 February 2026 - Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation of its fourth quarter 2025 results on Thursday, 12 February 2026.

The presentation can be followed live via a webcast link available on www.zelluna.com at 08:30 CET on Thursday, 12 February 2026. The webcast recording will remain available on the company's website after the event, and participants will be able to submit questions during the presentation.

The quarterly report and presentation materials will be published on the company's website at 07:00 CET on the same day.

For further information, please see www.zelluna.com or contact:

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA Email: namir.hassan@zelluna.com (https://www.globenewswire.com/Tracker?data=Z8lLmV- B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov) Phone: +44 7720 687608

Geir Christian Melen, CFO, Zelluna ASA Email: geir.christian.melen@zelluna.com (mailto:geir.christian.melen@zelluna.com) Phone: +47 913 02 965